Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Cash from Financing Activities (2016 - 2026)

Champions Oncology has reported Cash from Financing Activities over the past 17 years, most recently at -$36000.0 for Q1 2026.

  • For Q1 2026, Cash from Financing Activities changed N/A year-over-year to -$36000.0; the TTM value through Jan 2026 reached $86000.0, down 47.88%, while the annual FY2025 figure was $170000.0, 132.26% up from the prior year.
  • Cash from Financing Activities for Q1 2026 was -$36000.0 at Champions Oncology, down from $168000.0 in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $239000.0 in Q4 2024 and troughed at -$590000.0 in Q3 2023.
  • A 5-year average of -$10285.7 and a median of -$23000.0 in 2025 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: soared 221.43% in 2022 and later crashed 568.75% in 2023.
  • Year by year, Cash from Financing Activities stood at $86000.0 in 2022, then surged by 55.81% to $134000.0 in 2023, then skyrocketed by 78.36% to $239000.0 in 2024, then dropped by 29.71% to $168000.0 in 2025, then crashed by 121.43% to -$36000.0 in 2026.
  • Business Quant data shows Cash from Financing Activities for CSBR at -$36000.0 in Q1 2026, $168000.0 in Q4 2025, and -$14000.0 in Q3 2025.